A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Body Mass Index 30 to 45 Exclusion Criteria: * Type 2 Diabetes Mellitus * Multiple Endocrine Neoplasia Type 2 * Medullary thyroid cancer
About the study
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
What is being tested
- Semaglutide 6 mg liquid emulsion formulation (drug)
- Wegovy® (semaglutide) Tablet (drug)
- Placebo liquid emulsion formulation (drug)
Sponsor: Gila Therapeutics, Inc. · Participants: 40 · Started: Jun 17, 2026
Contact the study team
Official record on ClinicalTrials.gov — NCT07728383
Locations in the U.S.
| Minnesota | Clinical Research Institute of Minnesota, Minneapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.